Proactive Investors - Run By Investors For Investors

UPDATE - Verona Pharma making significant headway

UPDATE - Verona Pharma making significant headway
Researchers already know RPL554 is well tolerated, and they have been able to increase the safe dose to 16 times higher than previously used.


Annual results from Verona Pharma (LON:VRP) reflected a year of progress for the Cardiff-based biotech and its drug candidate, RPL554, being developed to treat the effects of lung disease.

The most important financial landmark was last March’s successful £14mln fundraiser to bankroll its lead compound.

Researchers already know RPL554 is well tolerated, and they have been able to increase the safe dose to significantly.

They have also begun a phase I/II study and interim data has revealed the latest formulation could be administered twice daily. 

The full results of the trial are expected later this year.

RPL554 is unique in that it is both a bronchodilator, which makes breathing easier by relaxing muscles in the lung, and it has anti-inflammatory properties.

Currently, it is being developed to treat a chronic obstructive pulmonary disease, a collection of ailments usually linked with smoking.

However Verona is also exploring RPL554’s potential use in cystic fibrosis.

“We remain confident that with multiple potential applications, each representing an attractive commercial opportunity, RPL554 has the potential to generate significant value for shareholders," chief executive Jan-Anders Karlsson told investors.

Unsurprisingly for a company at this formative stage of its development, Verona posted a loss (the shortfall £2.76mln). The cash outflow was £3.83mln, up from £2.34mln previous and reflecting the ramp up in activity.

The shares, up 180% in the year to date, marked time at 3.38p, valuing the business at £34mln.

“We believe the potential strategic value of Verona Pharma and RPL554 could generate attractive returns to shareholders,” said Sheena Berry, at City broker at N+1 Singer.

View full VRP profile View Profile

Verona Pharma Timeline

June 20 2016
November 26 2010

Related Articles

young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Woman touching face
May 01 2019
The SkinBiotix platform uses lysates (extracts) of probiotic bacteria to help increase the integrity of the skin as a barrier against toxins and other harmful elements while also improving its healing rate and infection resistance
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use